Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery

Brief description of study

The purpose of this study is to see if 3.0mg liraglutide (Saxenda®) is safe and able to help patients achieve weight loss after experiencing weight regain at least 18 months following Roux-en-Y Gastric Bypass (RYGB). Liraglutide (Saxenda®) is approved by the US Food and Drug Administration (FDA) as an add-on therapy to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients who are either obese (with a body mass index (BMI) of 30 kg/m2 or more) or overweight (with a BMI of 27 kg/m2 or more) and have at least one weight-related condition such as high blood pressure, Type 2 diabetes, or dyslipidemia (high triglycerides, high “bad” cholesterol or low “good” cholesterol). Liraglutide (Saxenda®) will be used based on its approved labeling and recommended dose in this study. You may qualify for this study if you had a weight loss surgery called gastric bypass surgery at least 18 months ago and then regained some of the weight you lost.

Clinical Study Identifier: s16-01527 Identifier: NCTs16-01527